TopNews

Two recently conducted studies have shown that two different classes of drugs can help to reduce the deaths caused due to breast cancer. The inexpensive drugs, aromatase inhibitors (AIs) and bisphosphonates, can improve survival prospects for postmenopausal women with early breast cancer.

The study researchers suggested that the two types of drug could be used together, increasing the benefits and decreasing some side-effects.

Lead author of both studies Professor Richard Gray, from the University of Oxford, UK said in a statement that the studies provide a clear evidence that both of these inexpensive, generic drugs could help to reduce breast cancer mortality in postmenopausal women.

A recently conducted study has revealed that several hospitals in the United States overestimate their ability to provide fast delivery of tissue plasminogen activator (tPA) to stroke patients. The findings of the study were published online July 22 in the Journal of the American Heart Association.

The team of researchers for the study surveyed staff of nearly 141 hospitals across the country. These hospitals were those who treated nearly 48,201 stroke patients in 2009 and 2010.

It has been said that hospitals surveyed in the study participated in the American Heart Association's 'Get with the Guidelines: Stroke' program, which aimed to improve stroke care.

The Alzheimer's Association global Conference that happened this week provided an opportunity to dementia researchers across the globe to come and discuss the findings of their research papers. The conference that happened in Washington, D. C., heard some positive news.

One of the studies has unveiled that a therapy has proved to be quite beneficial. It is an aerobic exercise that is cost-effective and free from side effects. The study involving elderly with mild cognitive impairment has found that regular intensive aerobic exercise was able to reduce the tau protein's quantity found in regular intensive aerobic exercise.

A research published in the Journal of the American Medical Association (JAMA) Oncology has unveiled that chemotherapy is not a good option when a person is suffering from end-stage cancer. The researchers said that it would do more harm than good.

In the study, more than 300 patients suffering from metastatic cancer were involved. These patients were the ones whose tumor had crossed the initial stage and has spread into other organs as well and had become incurable.

The study researchers said that around 50% of the patients were taking chemotherapy, a process in which strong chemicals are delivered into the body to destroy cancer cells and reduce the size of tumors.

It has been said that the first ever malaria vaccine has been approved on Friday by European drugs regulators. The European drug regulators recommended that the drug should be licensed to be used on babies in Africa who are at high risk of the mosquito-borne disease.

The vaccine called RTS, S or Mosquirix has been developed by British drugmaker GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative. The vaccine is said to be the first ever licensed human vaccine against a parasitic disease.

Drug makers said that it could efficiently help prevent millions of cases of malaria in countries that will use it. Recommendations for a drug license made by the European Medicines Agency (EMA) are normally endorsed by the European Commission within a couple of months.

The European Space Agency (ESA) has been continuously trying to active a set of commands that could help Philae to wake up and re-commence its scientific measures. Philae lander after landing on comet 67P/Churyumov- Gerasimenko in November unexpectedly bounced into a shadow and lost contact.

It has been told that until July 24, Rosetta will orbit a path that might allow it to contact the lander and then it will fly over the southern hemisphere of the comet to observe it with its own 11 instruments.

The agency told that despite the loss, the orbiter has tried to collect as much information as possible about the comet as it nears its closest encounter with the Sun, known as perihelion.